BRÈVE

sur Evotec AG (NASDAQ:EVTCY)

Evotec AG Introduces J.TRAIN for Efficient Biologics Manufacturing

Evotec SE has launched J.TRAIN, expanding its Just – Evotec Biologics services. This new offering allows biopharmaceutical companies to implement Evotec’s continuous manufacturing technology within their facilities, promising a significant boost in productivity and cost efficiency compared to traditional fed-batch techniques.

The J.TRAIN model features modular manufacturing infrastructure, which combines prefabricated cleanrooms with industry-standard equipment, supported by Just – Evotec Biologics’ cGMP-compliant process automation. This setup is designed to enable rapid and cost-effective scaling of biologics manufacturing, with deployments expected as fast as 18 months.

Unveiled at New York City's INTERPHEX conference, J.TRAIN highlights its ability to produce over 500 kilograms of drug substance in compact spaces, offering flexibility and lower operating costs. It facilitates quick transitions between products, reducing downtime and supporting diverse manufacturing environments.

R. P.

Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Evotec AG